Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

615 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.
Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA; ART Cohort Collaboration. Egger M, et al. Among authors: lundgren jd. Lancet. 2002 Jul 13;360(9327):119-29. doi: 10.1016/s0140-6736(02)09411-4. Lancet. 2002. PMID: 12126821
Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts.
Miller V, Phillips AN, Clotet B, Mocroft A, Ledergerber B, Kirk O, Ormaasen V, Gargalianos-Kakolyris P, Vella S, Lundgren JD. Miller V, et al. Among authors: lundgren jd. J Infect Dis. 2002 Jul 15;186(2):189-97. doi: 10.1086/341466. Epub 2002 Jul 3. J Infect Dis. 2002. PMID: 12134254 Free article. Clinical Trial.
Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy.
Kirk O, Reiss P, Uberti-Foppa C, Bickel M, Gerstoft J, Pradier C, Wit FW, Ledergerber B, Lundgren JD, Furrer H; European HIV Cohorts. Kirk O, et al. Among authors: lundgren jd. Ann Intern Med. 2002 Aug 20;137(4):239-50. doi: 10.7326/0003-4819-137-4-200208200-00008. Ann Intern Med. 2002. PMID: 12186514
Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Mateu S, Law M, El-Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD; DAD study group. Friis-Møller N, et al. Among authors: lundgren jd. AIDS. 2003 May 23;17(8):1179-93. doi: 10.1097/01.aids.0000060358.78202.c1. AIDS. 2003. PMID: 12819520
Virological rebound after suppression on highly active antiretroviral therapy.
Mocroft A, Ruiz L, Reiss P, Ledergerber B, Katlama C, Lazzarin A, Goebel FD, Phillips AN, Clotet B, Lundgren JD; EuroSIDA study group. Mocroft A, et al. Among authors: lundgren jd. AIDS. 2003 Aug 15;17(12):1741-51. doi: 10.1097/00002030-200308150-00003. AIDS. 2003. PMID: 12891060
Combination antiretroviral therapy and the risk of myocardial infarction.
Friis-Møller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, Thiébaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD; Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Friis-Møller N, et al. Among authors: lundgren jd. N Engl J Med. 2003 Nov 20;349(21):1993-2003. doi: 10.1056/NEJMoa030218. N Engl J Med. 2003. PMID: 14627784 Free article.
615 results